Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06421701
Status:
RECRUITING
Last Update Posted:
2024-05-20
First Post:
2024-05-13
Brief Title:
Anti-CD19 CAR-NK Cells in RefractoryRelapsed Systemic Lupus Erythematosus
Sponsor:
Second Affiliated Hospital School of Medicine Zhejiang University
Organization:
Second Affiliated Hospital School of Medicine Zhejiang University
Study Overview
Official Title:
A Clinical Study of Anti-CD19 CAR-NK Cells in the Treatment of RefractoryRelapsed Systemic Lupus Erythematosus
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center open-label single-arm dose-escalation trial The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractoryrelapsed systemic lupus erythematosus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None